Imugene Limited Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.
Imugene, Investor Presentation 10/01/2019 09:45:00 HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY Investment Highlights Novel immuno-oncology B-cell peptide vaccine technology Outstanding scientific provenance from leading U.S. and European un…
Imugene Announces Appointment of Distinguished Scientist, Dr Michael Caligiuri of City of Hope to Scientific Advisory Board 08/01/2019 03:07:00 - President of City of Hope National Medical Center and holds the Deana and Steve Campbell Physician-in-Chief. - Elected President of the American Association for Cancer Research (AACR) in 2017, th…
Imugene Announces Endpoints Met in Phase 1b Gastric Cancer Immuno-oncology Trial 17/12/2018 10:00:00 Safety, tolerability & phase 2 dose determined Phase 2 trial first patient to be dosed early 2019 5 patients with partial responses 4 patients with stable disease SYDNEY, Australia…
Company News / by Anna Napoli - 13 days ago Imugene appoints distinguished scientist to SAB 07 Jan 2019 - Imugene (ASX:IMU) has today announced the appointment of distinguished scientist, Dr Michael Caligiuri to its Scientific Advisory Board.
Company Presentations / by - 2 months ago Imugene (ASX:IMU) Presentation, FNN Investor Event, October 2018, Sydney 26 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong presents on the company's trial progress with its lead HER-Vaxx cancer vaccine, advantages of B-cell…
Interviews / by Rachael Jones - 2 months ago Imugene (ASX:IMU) targeting gastric cancer 29 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong talks trial progress with the company's lead HER-Vaxx cancer vaccine, advantages of B-cell vaccines …
Market Reports / by Rachael Jones - 3 months ago Healthcare sector stays in the green: ASX closes 0.6% lower 01 Oct 2018 - It's been a quiet day on the markets with the ASX closing lower. New Zealand software company Xero did well today, Nufarm shares were down. The Canadian dollar and Me…
Company News / by Anna Napoli - 3 months ago Imugene appoints leading cancer researcher to board 01 Oct 2018 - Biotech company, Imugene (ASX:IMU) has today announced the appointment of a leading cancer researcher to its Scientific Advisory Board.
Company News / by Rachael Jones - 4 months ago Imugene starts manufacture of KEY-Vaxx for trials 21 Sep 2018 - Clinical stage immuno-oncology company Imugene (ASX:IMU) has formally commenced cGMP manufacture of the clinical batch of cancer vaccine KEY-Vaxx.
Company News / by Anna Napoli - 4 months ago Imugene completes recruitment for Phase 1b clinical trial of HER-Vaxx 11 Sep 2018 - Immuno-oncology company, Imugene (ASX:IMU) has announced the Phase 1b clinical trial of its cancer vaccine (HER-Vaxx) for gastric cancer patients has completed recrui…
Market Reports / by Jessica Amir - 7 months ago Out of puff on Friday: Aus shares close 0.9% higher on week 08 Jun 2018 - Market Wrap. ASX20, ASX50, ASX100 and ASX200 reshuffled with Afterpay Touch (ASX:APT) & Kidman Resources (ASX:KDR) in ASX200. MMJ PhyoTech (ASX:MMJ) pleased Canada cl…
Interviews / by Rachael Jones - 10 months ago Imugene (ASX:IMU) 1H18 results & outlook 09 March 2018 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks 1H18 and outlook, including progress with the company's lead HER-Vaxx cancer vaccine.
Company News / by Kathy Skantzos - A year ago Imugene raises $8.7 million for clinical trial 23 Nov 2017 - Immune-oncology company Imugene (ASX:IMU) raises $8.7 million through a $6.7 million institutional placement and a $2 million fully underwritten entitlement offer.
Company Presentations / by - A year ago Imugene (ASX:IMU) Presentation, FNN Small Cap Investor Event, October 2017, Sydney 12 Oct 2017 - Imugene Limited (ASX:IMU) CEO Leslie Chong presents at the FNN Small Cap Investor Event, October 2017, Sydney.
Interviews / by Jessica Amir - A year ago Imugene (ASX:IMU) talks Phase 1 & 2 cancer trials 11 Oct 2017 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks cancer trials for the company's lead drug candidate, HER-Vaxx, strategy and outlook.
Market Reports / by - 3 years ago Market Wrap: Aus shares close 0.48% lower 04 Jan 2016 - Aus shares close 0.48% lower. Amaysim Australia Limited (ASX:AYS) acquires mobile virtual network operator Vaya.
Company News / by - 3 years ago Imugene Vaxx shows dramatic improvement 20 Apr 2015 - Imugene Limited (ASX:IMU) says leading cancer vaccination is showing a dramatic ten-fold increase in antibodies and has met an additional milestone.
Market Reports / by - 4 years ago Midday: ASX follows global selloff 08 Oct 2014 - ASX follows global selloff. BC Iron Limited (ASX:BCI) increases its relevant interest in Iron Ore Holdings to 90.37%.
